Howard Marks, Oaktree Capital Management’s co-founder, will have treatment for a curable type of throat cancer, according to the Financial Times.
(Bloomberg) — Howard Marks, Oaktree Capital Management’s co-founder, will have treatment for a curable type of throat cancer, according to the Financial Times.
Marks, 77, will undergo surgery followed by radiation treatment, the newspaper reported, citing a letter to investors. He plans to return to work “around midsummer,” according to the report.
“I was recently diagnosed with a relatively common form of throat cancer,” the FT cited Marks as writing in a May 3 note to investors. “The treatment is pretty routine, and the probability of a cure in my case (cure, not remission) is estimated at between 95% and 99%.”
A representative for Oaktree declined to comment on the report.
Marks started Oaktree in 1995 with Bruce Karsh and other partners from TCW Group Inc. The Los Angeles-based firm is one of the largest distressed-debt investors in the world and had about $172 billion of assets under management at the end of March.
In 2019, Brookfield Asset Management acquired a majority interest in Oaktree and the firm operates as an independent business within the Brookfield universe. Marks remains the public face of the firm.
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.